Karen A. Foster, the Chief Quality and Operations Officer at Biolife Solutions Inc. (NASDAQ:BLFS), recently sold a portion of her company stock. According to a Form 4 filing with the Securities and ...

Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.

News 8 is once again honoring Black history by looking at health care and the racial disparities many report facing.

Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, ...

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...

Cell-engineering company, MaxCyte, Inc., announced it will acquire SeQure Dx, which focuses on editing assessment services for cell and gene therapies, for $4.5 million. The all-cash deal includes ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR-T cell therapy program for autoimmune diseases.